NEC Baby Formula Litigation: $495M Verdict Upheld, Federal Bellwether July 2026
Ongoing news coverage of MDL 3026 and parallel state-court litigation against Abbott and Mead Johnson. A $495 million verdict was upheld in May 2026. Federal bellwether trials start July 6.
By 411 Press Legal DeskUpdated 7 min read
This is an ongoing story. 411 Press updates this coverage as the litigation develops. Last updated: May 28, 2026.
Premature infants in neonatal intensive care units were fed cow's milk-based formula. Some developed necrotizing enterocolitis — a disease that destroys the bowels, requires emergency surgery, and kills 20% to 30% of the infants it affects. Medical research linking cow's milk formula to elevated NEC risk in preterm infants spans decades. The formula manufacturers had it.
Families are suing Abbott Laboratories (Similac) and Mead Johnson (Enfamil), alleging failure to warn NICUs and parents about the documented risk. Juries are agreeing. A Missouri jury returned $495 million against Abbott in July 2024. A Chicago jury returned $70 million in April 2026. The Missouri Court of Appeals upheld the $495 million verdict in May 2026. Federal bellwether trials begin July 6.
| Total Cases | 1,700+ (including 797 in MDL 3026 as of May 2026) |
| MDL Number | 3026 |
| Court | Northern District of Illinois |
| Defendants | Abbott Laboratories (Similac), Mead Johnson / Reckitt Benckiser (Enfamil) |
| Largest Verdict | $495M (Missouri, July 2024 — upheld on appeal May 2026) |
| Most Recent Verdict | $70M to four families (Chicago, April 2026) |
| Next Bellwether Trial | July 6, 2026 (Enfamil case) |
Where the MDL Stands
MDL 3026 is consolidated in the Northern District of Illinois. As of May 2026, 797 cases are pending in the federal MDL, with over 1,700 total cases including state court filings.
The federal litigation has been running parallel to state court trials in Missouri and Illinois. Those state trials have produced verdicts. The federal MDL has not gone to bellwether yet.
That changes July 6, 2026. The first federal MDL trial is scheduled — an Enfamil (Mead Johnson) case, making it the first federal trial against the second major defendant. A second bellwether trial involving Similac (Abbott) is scheduled for August 10, 2026. Additional trials are scheduled for November 2, 2026, and February 1, 2027.
The bellwether outcomes will set expectations for the remaining cases. The state-court verdicts have established that juries will find for plaintiffs — and award significant punitive damages — when the failure-to-warn evidence is presented.
The Verdicts So Far
The NEC litigation has produced the strongest verdict track record of any active mass tort. Four favorable verdicts. No defense wins.
| Case | Date | Defendant | Amount | Detail |
|---|---|---|---|---|
| Gill v. Abbott (Missouri) | July 2024 | Abbott | $495M | $95M compensatory + $400M punitive. Upheld on appeal May 2026. |
| Baumgardner v. Mead Johnson (Illinois) | 2024 | Mead Johnson | $60M | Mother of premature infant who died after being fed Enfamil. |
| Four families v. Abbott (Chicago) | April 2026 | Abbott | $70M | Cook County jury. Similac Special Care formula. |
| State trial v. Abbott | April 2026 | Abbott | $53M | Second 2026 state-court verdict. |
The Missouri Court of Appeals upheld the $495 million Gill verdict in May 2026. The $400 million punitive component is the part that signals how juries are reading the conduct. Punitive damages of that magnitude — more than four times compensatory — reflect a finding that goes beyond negligence to something a jury believed warranted punishment. Abbott has indicated it will continue to appeal.
Published projections for individual settlements, based on verdict data, range from $45,000 for less severe medical NEC cases to over $600,000 for cases involving infant death. These are projections from law firms, not confirmed settlement amounts.
Why NEC Cases Are Going to Trial
In most mass tort litigation, defendants settle before trial. Pharmaceutical manufacturers, medical device makers, chemical companies — they typically resolve through global settlement frameworks once bellwether verdicts establish liability.
Abbott and Mead Johnson are going to trial. Four times. Losing four times.
The reason, according to industry observers, is the strength of the medical literature against the formula manufacturers. The claim is not novel science requiring extensive Daubert litigation. The link between cow's milk-based formula and elevated NEC risk in premature infants has been documented in peer-reviewed research for decades.
A widely cited Cochrane systematic review examined multiple studies comparing formula feeding to breast milk feeding in premature infants and found significantly higher NEC rates in formula-fed groups. Research indicates that exclusively human milk-fed premature infants have up to a 90% lower risk of developing surgical NEC compared to those receiving cow's milk-based products.
The biological mechanism is understood. Premature infants have immature intestinal barriers and underdeveloped immune systems. Cow's milk proteins can trigger inflammatory responses in the immature gut. The danger is specific to premature infants — full-term infants digest cow's milk-based formula without the same risk.
The litigation does not allege the formula products are defective for all infants. The claim is narrow and specific: Abbott and Mead Johnson marketed specialized premature infant formulations — Similac Special Care, Enfamil Premature — directly to NICUs. The labels and marketing materials did not adequately disclose the elevated NEC risk associated with cow's milk-based formula in premature infants. The duty to warn was clear. The warning was not given.
In 2024, the FDA, NIH, and CDC released a joint statement noting there is "no conclusive evidence that preterm infant formula causes NEC." The agencies acknowledged that human milk is protective against NEC — meaning the absence of human milk (i.e., the use of formula) is associated with higher risk. That distinction between "causes" and "associated with elevated risk" is the regulatory hedge. The juries have not been persuaded by it.
What's Next
July 6, 2026 — First federal bellwether. Enfamil case (Mead Johnson). First federal trial against the second major defendant. Outcome will heavily influence settlement negotiations.
August 10, 2026 — Second federal bellwether. Similac case (Abbott). The largest defendant has lost four state-court trials. A federal verdict against Abbott would intensify settlement pressure.
November 2, 2026 — Third federal bellwether. Defendant not yet specified in court schedule.
February 1, 2027 — Fourth federal bellwether.
Global settlement framework — not yet announced. The pattern in mass torts with strong plaintiff verdict records is settlement following bellwether outcomes. Based on the current trajectory, settlement frameworks could develop within 1-2 years.
Background: What Is NEC
Necrotizing enterocolitis primarily affects premature infants. The intestinal wall becomes inflamed, tissue dies, and in severe cases a hole develops in the intestine. Bacteria leak into the abdomen. Life-threatening infection follows.
Symptoms typically appear within the first 2-6 weeks of life: abdominal swelling, feeding intolerance, bloody stool, lethargy, temperature instability.
Treatment depends on severity. Medical NEC is treated with antibiotics, bowel rest, and IV nutrition. Surgical NEC requires emergency surgery to remove dead intestinal tissue. Some infants need an ostomy. In the most severe cases, so much intestine is destroyed that the infant develops short bowel syndrome — a lifelong condition.
Mortality runs 20% to 30% across the affected population. Rates are higher among the smallest and most premature infants.
The products at the center of the litigation are Abbott's Similac line (Similac Special Care, Similac Human Milk Fortifier, Similac NeoSure, and other NICU formulations) and Mead Johnson / Reckitt Benckiser's Enfamil line (Enfamil Premature, Enfamil Human Milk Fortifier, Enfamil NeuroPro EnfaCare, and similar products). Store-brand equivalents of cow's milk-based premature infant formula also appear in court filings. The products have not been recalled.
More Coverage
Recent 411 Press reporting on the infant formula safety and NICU accountability beats:
Coverage tags: NEC · Abbott · Mead Johnson · Infant Formula
Related litigation we are tracking:
- Ozempic / GLP-1 MDL — 3,722+ cases pending
- Camp Lejeune Litigation — ~$571M paid of ~$795M approved, ~407,000 claims
- Hair Relaxer MDL — 11,526 pending cases
- Social Media Addiction MDL — 2,527 pending cases, $6M verdict
411 Press monitors the NEC baby formula MDL and state court proceedings and publishes updates as developments occur. We'll publish more as we find out. For our reporting methodology and sourcing standards, see our editorial standards.
Related coverage
